2-Phenyl<1H>pyrrolo<2,3-d>pyrimidine | 139962-80-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 2-Phenyl<1H>pyrrolo<2,3-d>pyrimidine
• 英文别名: 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine
• CAS: 139962-80-4
• 化学式: C₁₂H₉N₃
• 分子量: 195.224
• InChiKey: PAWABSCCOFXOCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-氨基-5-溴嘧啶 、 苯乙酮 在 allyl(1,3-bis(2,6-diisopropylphenyl)imidazolidin-2-ylidene)palladium(IV) chloride 、 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 6.08h， 以62%的产率得到2-Phenyl<1H>pyrrolo<2,3-d>pyrimidine
  参考文献：
  名称：

  One-Pot Synthesis of Azaindoles via Palladium-Catalyzed α-Heteroarylation of Ketone Enolates

  摘要：

  A convenient, one-pot method for the construction of a variety of azaindoles using simple ketones and haloamino-pyridines is described.

  DOI：

  10.1021/jo100623d

文献信息

• Reactions of β-(lithiomethyl)azines with nitriles as a route to pyrrolo-pyridines, -quinolines, -pyrazines, -quinoxalines and -pyrimidines
  作者：Michael L. Davis、Basil J. Wakefield、Jacklyn A. Wardell

  DOI：10.1016/s0040-4020(01)88196-5

  日期：——

  Deprotonation of 3-methylazines, followed by reaction with benzonitile, gives an intermediate which, on treatment with additional strong base, cyclises to give 2-phenyl[1H]-pyrrolo[2,3-b]pyridine. The application of this type of reaction to a variety of nitriles and β-methylazines (pyridines, quinolines, pyridines, quinoxalines and pyrimidines) is described.

  3-甲基嗪的去质子化，然后与苯甲腈反应，得到一种中间体，该中间体在用另外的强碱处理后，环化成2-苯基[1H]-吡咯并[2,3-b]吡啶。描述了将这种类型的反应应用于各种腈和β-甲基嗪（吡啶，喹啉，吡啶，喹喔啉和嘧啶）。
• Combination anti-cancer therapy
  申请人：Bhagwat Shripad

  公开号：US20090274698A1

  公开（公告）日：2009-11-05

  The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. Examples of such anti-cancer agents or treatments include doxorubicin, cisplatin, or ionizing radiation. The present invention also provides a pharmaceutical composition comprising an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. The present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of the anti-cancer agent melphalan or 5-FU, and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases.

  本发明提供了一种治疗患者肿瘤或肿瘤转移的方法，包括同时或顺序给患者施用抗癌药物或提高肿瘤细胞pAkt水平的治疗剂量和结合并直接抑制mTORC1和mTORC2激酶的mTOR抑制剂。这样的抗癌药物或治疗剂包括多柔比星、顺铂或电离辐射。本发明还提供了一种药物组合，包括抗癌药物或提高肿瘤细胞pAkt水平的治疗剂量和结合并直接抑制mTORC1和mTORC2激酶的mTOR抑制剂，以及药学上可接受的载体。本发明还提供了一种治疗患者肿瘤或肿瘤转移的方法，包括同时或顺序给患者施用治疗剂量的抗癌药物美法仑或5-FU和结合并直接抑制mTORC1和mTORC2激酶的mTOR抑制剂。
• BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO KINASE INHIBITORS
  申请人：OSI Pharmaceuticals, Inc.

  公开号：EP2134860A1

  公开（公告）日：2009-12-23
• COMBINATION ANTI-CANCER THERAPY
  申请人：OSI Pharmaceuticals, Inc.

  公开号：EP2173338A1

  公开（公告）日：2010-04-14
• COMBINATION ANTI-CANCER THERAPY COMPRISING AN INHIBITOR OF BOTH MTORC1 AND MTORC2
  申请人：OSI Pharmaceuticals, Inc.

  公开号：EP2178563A2

  公开（公告）日：2010-04-28